No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 24 of the 40 quarters in the window, leaving 16 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 0.3x · 10Y median 11.4x · 1st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:19:02.286Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Beyond Air, Inc. (XAIR) stock was $2.65 as of Oct 6, 2026, 3:13 PM EDT, down 6.69% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -94.1% · 3-year avg -85.6%/yr · 5-year avg -76.7%/yr
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions.
Medical - Devices · Garden City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-03-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-3.31
Revenue Est.
$2.01M
Last Quarter Results
EPS
$-30.60
vs Estimate
$-26.40
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1XAIR | $1.91M | $2.65 | -6.69% | -94.08% | -76.73% | N/A | N/A |
| 2AMIX | $1.91M | $3.51 | -0.85% | -85.08% | N/A | N/A | vs XAIR |
| 3PFSA | $1.86M | $1.69 | -3.71% | -99.93% | N/A | N/A | vs XAIR |
| 4TNON | $1.85M | $3.73 | +0.81% | -91.30% | N/A | N/A | vs XAIR |
| 5RNAZ | $1.83M | $1.73 | -1.99% | -83.28% | -93.39% | N/A | vs XAIR |
| 6TCRT | $1.80M | $0.74 | -7.17% | -68.76% | -69.13% | -50.22% | vs XAIR |
forward FY estimate
N/A
$1.77M
vs Estimate
$1.93M
Consensus Rating
Based on 2 analysts
Average Price Target
$20.00
+654.7% upside
Low
$10.00
Current
$2.65
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-3.90 | $-3.31 | $-2.73 | 2 |
| Quarter ending Dec 2026 | $-2.22 | $-2.22 | $-2.22 | 1 |
| Quarter ending Mar 2027 | $-2.74 | $-2.74 | $-2.74 | 1 |
| Quarter ending Jun 2027 | $-2.53 | $-2.53 | $-2.53 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-22.71 | $-22.71 | $-22.71 | 1 |
| FY 2028 | $-8.04 | $-8.04 | $-8.04 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.00M | $2.01M | $2.03M | 2 |
| Quarter ending Dec 2026 | $2.30M | $2.30M | $2.30M | 1 |
| Quarter ending Mar 2027 | $3.00M | $3.00M | $3.00M | 1 |
| Quarter ending Jun 2027 | $3.50M | $3.50M | $3.50M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $8.00M | $8.00M | $8.00M | 1 |
| FY 2028 | $16.72M | $16.72M | $16.72M | 1 |
